Pittenger G, et al. A 6-month, randomized, double-masked, placebo-controlled study evaluating
Topical capsaicin for pain management: therapeutic Er, it may be identified in childhood or late adulthood, although prospective and mechanisms of action with the new high-concentration capsaicin eight patch. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the therapy of postherpetic neuralgia. Discomfort Med. 2011;12:99?01.Pittenger G, et al. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care. 2007;30:896?02. 22. Maier C, Baron R, T le TR, et al. Quantitative sensory testing within the German research network on neuropathic discomfort (DFNS): somatosensory abnormalities in 1236 patients with distinct neuropathic discomfort syndromes. Pain. 2010;150: 439?0. 23. Backonja MM, Attal N, Baron R, et al. Worth of quantitative sensory testing in neurological and pain issues: NeuPSIG consensus. Discomfort. 2013;154:1807?9.References 1. Jensen MP, Chodroff MJ, Dworkin RH, et al. The impact of neuropathic discomfort on health-related quality of life: critique and implications. Neurology. 2007; 68:1178?two. 2. T le T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of well being state impairment and remedy patterns. J Diabetes Complicat. 2006;20:26?3. three. Schmader KE. Epidemiology and impact on good quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350?. four. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in variety 2 diabetes. Diabetes Care. 2006;29:1518?2. 5. Huizinga MM, Peltier A. Painful diabetic neuropathy: a managementcentered review. Clin Diabetes. 2007;25:six?five. six. Jensen TS, Backonja MM, Hern dez Jim ez S, et al. New perspectives around the management of diabetic peripheral neuropathic discomfort. Diab Vasc PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26577270 Dis Res. 2006;3:108?9. 7. Rudroju N, Bansal D, Talakokkula ST, et al. Comparative efficacy and security of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Discomfort Physician. 2013;16:E705?4. 8. Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for remedy of discomfort linked with diabetic neuropathy: final results of two randomized, doubleblind, placebo-controlled studies. Discomfort. 2007;128:169?9. 9. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28878015 review and meta-analysis. Lancet Neurol. 2015;14:162?three. ten. Anand P, Bley K. Topical capsaicin for pain management: therapeutic prospective and mechanisms of action with the new high-concentration capsaicin 8 patch. Br J Anaesth. 2011;107:490?02. 11. Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the remedy of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7:1106?two. 12. Brown S, Simpson DM, Moyle G, et al. NGX-4010, a capsaicin eight patch, for the therapy of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials. AIDS Res Ther. 2013;ten:5. 13. Haanp M, Cruccu G, Nurmikko T, et al. Capsaicin 8 patch versus oral pregabalin in sufferers with peripheral neuropathic pain.